Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
---|
05/03/2000 | CN1251771A Medicine for treating diabetes |
05/03/2000 | CN1051921C Methods of inhibiting imperfect tissue repair |
05/02/2000 | US6057454 1-oxo-1H-inden-2-yl-1H-imidazole-2-carboxylic acid intermediates |
05/02/2000 | US6057450 Derivatives of pyroglutaminic acid preparation process and applications |
05/02/2000 | US6057440 Process for preparing bis-indoly macrocycles |
05/02/2000 | US6057369 Use in the treatment of disease states associated with proteins that mediate cellular activity which are capable of being modulated by inhibiting a matrix metalloproteinase (mmp), tumor necrosis factor (tnf) or cyclic amp |
05/02/2000 | US6057349 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxphenyl, and aminophenyl alkylsulfonamides and ureas and their use |
05/02/2000 | US6057341 Bi-aromatic dibenzofuran derivatives and their use in human and veterinary medicine and in cosmetics |
05/02/2000 | US6057338 Useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy |
05/02/2000 | US6057317 Heterocyclic compounds |
05/02/2000 | US6057294 Peptide |
05/02/2000 | US6057292 Method for inhibiting growth hormone action |
05/02/2000 | US6057287 Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
05/02/2000 | US6056977 Once-a-day controlled release sulfonylurea formulation |
05/02/2000 | US6055936 Sea cucumber carotenoid lipid fractions and process |
05/02/2000 | CA2076018C Docosahexaenoic acid, methods for its production and compounds containing the same |
05/02/2000 | CA2069961C Method and compositions for inhibition of disorders associated with oxidative damage |
04/27/2000 | WO2000023784A2 Method of detecting risk of type ii diabetes based on mutations found in carboxypeptidase e |
04/27/2000 | WO2000023603A2 Methods of treatment of type 2 diabetes |
04/27/2000 | WO2000023601A1 Delivery system for porcine somatotropin |
04/27/2000 | WO2000023572A1 Tnfr related gene 12 |
04/27/2000 | WO2000023471A2 Use of a cytokine-producing lactococcus strain to treat colitis |
04/27/2000 | WO2000023457A1 Adenine derivatives |
04/27/2000 | WO2000023451A1 New compounds, their preparation and use |
04/27/2000 | WO2000023445A1 New compounds, their preparation and use |
04/27/2000 | WO2000023437A1 Nitrogenous fused heterocycle compounds, process for the preparation thereof and agents containing the same |
04/27/2000 | WO2000023428A1 1,5-benzodiazepine compounds, process for producing the same, and medicine |
04/27/2000 | WO2000023425A1 New compounds, their preparation and use |
04/27/2000 | WO2000023417A1 New compounds, their preparation and use |
04/27/2000 | WO2000023416A1 New compounds, their preparation and use |
04/27/2000 | WO2000023415A1 New compounds, their preparation and use |
04/27/2000 | WO2000023407A2 Ureido-thiobutyric acid derivatives as ppar-agonists |
04/27/2000 | WO2000023100A2 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
04/27/2000 | WO2000023099A1 Insulin preparations for pulmonary delivery containing menthol |
04/27/2000 | WO2000023098A1 Stable concentrated insulin preparations for pulmonary delivery |
04/27/2000 | WO2000023097A1 Use of growth hormone or analogues thereof for the treatment of mammals with familial hypercholesterolemia |
04/27/2000 | WO2000023091A2 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
04/27/2000 | WO2000023074A1 Pharmaceutical composition containing decursin |
04/27/2000 | WO2000023069A1 Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiquinones and methods of using same |
04/27/2000 | WO2000023063A2 Methods for inhibiting diabetic complications |
04/27/2000 | WO2000023053A2 Artificial antigen-specific cells and related methods |
04/27/2000 | WO2000007014A3 Leptin-mediated gene-induction |
04/27/2000 | WO2000004895A3 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
04/27/2000 | CA2347938A1 1,5-benzodiazepine compounds, their production and use |
04/27/2000 | CA2347625A1 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
04/27/2000 | CA2347095A1 Nitrogen-containing condensed heterocyclic derivatives, their production and agent |
04/27/2000 | CA2347080A1 Tnfr related gene 12 |
04/27/2000 | CA2346969A1 Stable concentrated insulin preparations for pulmonary delivery |
04/27/2000 | CA2346937A1 Specific therapeutic interventions obtained by interference with redistribution and/or targeting |
04/27/2000 | CA2346884A1 Insulin preparations for pulmonary delivery containing menthol |
04/27/2000 | CA2346799A1 Delivery system for porcine somatotropin |
04/27/2000 | CA2346325A1 Bioflavonoids as plasma high density lipoprotein level increasing agent |
04/27/2000 | CA2342794A1 Use of growth hormone or analogues thereof for the treatment of mammals with familial hypercholesterolemia |
04/27/2000 | CA2267488A1 Weight control product and method of treating hyperlipidemia and increasing vigor with said product |
04/26/2000 | EP0995756A2 Mechanism oriented inhibitors of dipeptidyl peptidase I |
04/26/2000 | EP0994872A1 4-phenylpiperidine compounds |
04/26/2000 | EP0994870A1 Novel aryloxy substituted pyrimidine imidazole compounds |
04/26/2000 | EP0994860A1 Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
04/26/2000 | EP0994854A1 Method for preparing a substituted perhydroisoindole |
04/26/2000 | EP0994717A1 Treatment of autoimmune disease using tolerization in combination with methotrexate |
04/26/2000 | EP0994716A1 Maternal immune secretions and their use in the treatment and/or prophylaxis of conditions of the human body |
04/26/2000 | EP0994708A1 Antagonists of gonadotropin releasing hormone |
04/26/2000 | EP0994705A1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
04/26/2000 | EP0994657A1 Palatable elemental medical food |
04/26/2000 | EP0994655A1 Satiety product |
04/26/2000 | EP0925305B1 Cyclitol containing carbohydrates from human tissue which regulate lipogenic activity |
04/26/2000 | EP0554381B2 Use of protective agents against reactive oxygen species |
04/26/2000 | CN1251574A Process for preparing O-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides |
04/26/2000 | CN1251573A Solid composition suitable for oral administration comprising non hydroscopic salts of L-carnitine or alkanoyl-L-carnitine with 2-aminoethanesulfonic acid |
04/26/2000 | CN1251572A Solid compositions suitable for oral administration composing L-carnitine and alkanoyl-L-carnitine mangesium tartrate |
04/26/2000 | CN1251521A Compound and method for therapeutic intervention in preventing diabetic complications |
04/26/2000 | CN1051769C Parathyroid hormone analogues, their production method and medicinal composition containing same |
04/26/2000 | CN1051762C Vitamin D3 analogs, preparation method and use, and medicinal composition containing same |
04/26/2000 | CN1051704C Composition containing retionic acids and tocopherol |
04/25/2000 | US6054590 Imidazolone anorectic agents: II. phenyl derivatives |
04/25/2000 | US6054578 Method for adsorbing cholesterol oxide, and process for producing foods containing cholesterol or cholesterol oxide |
04/25/2000 | US6054470 Src family SH2 domain inhibitors |
04/25/2000 | US6054457 Benzamide derivatives and their use as vasopressin antagonists |
04/25/2000 | US6054446 17-substituted-17-desoxy-1,3,5-estratrienes. |
04/25/2000 | US6054431 Anti-gram-positive bacterial methods and materials |
04/25/2000 | US6054428 Allow the toxic effects of cytotoxic drugs, e.g., cyclosporin, when used at high dosages or over prolonged times to be alleviated or even suppressed. |
04/25/2000 | US6054129 Flavor-improved extract from Cassia mimosoides L. var. nomame Makino and method of preparing the same |
04/25/2000 | CA2143849C Substituted thiazolidinedione derivatives |
04/20/2000 | WO2000022143A2 Protein kinase homologs |
04/20/2000 | WO2000021986A2 Matrix-remodeling genes |
04/20/2000 | WO2000021979A2 Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
04/20/2000 | WO2000021959A1 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
04/20/2000 | WO2000021955A1 Quinazoline derivatives |
04/20/2000 | WO2000021927A2 Pyrrole-2,5-diones as gsk-3 inhibitors |
04/20/2000 | WO2000021910A2 1,2-disubstituted cyclopropanes |
04/20/2000 | WO2000021574A2 Site-directed dual pegylation of proteins |
04/20/2000 | WO2000021557A1 Delta 6 fatty acid desaturase |
04/20/2000 | WO2000021554A1 Preventives or remedies for cachexia |
04/20/2000 | WO2000021541A1 Process for the preparation of oral pharmaceutical compositions comprising biphosphonates |
04/20/2000 | WO2000021540A1 Compositions containing diphosphonic acids |
04/20/2000 | WO2000021535A1 Pharmaceutical formulations for use in estrogen deprivation syndrome |
04/20/2000 | WO2000021525A2 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
04/20/2000 | WO2000021524A1 Pufa supplements |
04/20/2000 | WO2000021509A2 Methods of treatment |
04/20/2000 | WO2000021486A2 Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid |